Antioxidants for hypertension

Current Opinion in Nephrology and Hypertension

Volumn 7, Issue 5, 1998, Pages 531-538

  Kitiyakara, Chagriya ^a   Wilcox, Christopher S ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT;

ANTIOXIDANT ACTIVITY; HYPERTENSION; KIDNEY BLOOD FLOW; MAMMAL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

ANIMALS; ANTIOXIDANTS; HUMANS; HYPERTENSION; REACTIVE OXYGEN SPECIES;

EID: 0031686294     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199809000-00008     Document Type: Review

References (61)

1. Yu BP. Cellular defenses against damage from reactive oxygen species. Physiol Rev 1994; 74:139-162.
2. Halliwell B. Drug antioxidant effects. A basis for drug selection? Drugs 1991; 42:569-605.
3. Katusic ZS. Superoxide anion and endothelial regulation of arterial tone. Free Radic Biol Med 1996; 20:443-448.
4. Rosen GM, Pou S, Ramos CL, Cohen MS, Britigan BE. Free radicals and phagocytic cells. FASEB J 1995; 9:200-209.
5. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148.
6. Dean RT, Fu S, Stocker R, Davies MJ. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997; 324:1-18.
7. Diaz MN, Frei B, Vita JA, Keaney JF. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337:408-416.
8. Iuliano L, Colavita AR, Leo R, Pratico D, Violi F. Oxygen free radicals and platelet activation. Free Radic Biol Med 1997; 22:999-1006.
9. Cheng JJ, Wung BS, Choa YJ, Wang DL. Cyclic strain-induced reactive oxygen species involved in ICAM-1 gene induction in endothelial cells. Hypertens 1998; 31:125-130.
10. Clutton S. The importance of oxidative stress in apoptosis. Br Med Bull 1997; 53:662-668.
11. Suzuki YJ, Forman HJ, Sevenian A. Oxidants as stimulators of signal transduction. Free Radic Biol Med 1997; 22:269-285.
12. Poli G, Parola M. Oxidative damage and librogenesis. Free Radic Biol Med 1997; 22:287-305.
13. Li PF, Dietz R, Von Hardorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of smooth muscle cells. Circulation 1997; 96:3602-3609.
14. Landino LM, Crews BC, Timmons MD, Morrow JD, Marnett LJ. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci USA 1996; 93:15069-15074.
15. Pomposiello SI, Yang XP, Liu YH, Surakanti M, Rhaleb NE, Sevilla M, Carretero OA. Autocoids mediate coronary vasoconstriction induced by nitric oxide synthesis inhibition. J Cardiovasc Pharmacol 1997; 30:599-606.
16. Diederich D, Yang Z, Buhler FR, Luscher TF. Impaired endothelium-dependent relaxations in the hypertensive resistance arteries involve the cyclooxygenase pathway. Am J Physiol 1990; 258:H445-451
17. Roberts II LJ, Morrow JD. The generation and actions of isoprostanes. Biochim Biophys Acta 1997; 1345:121-135.
18. Zou MH, Ullrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine prostacyclin synthase. FEBS Lett 1996; 382:101-104.
19. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 1996; 271:C1424-C1437.
20. Pfeiffer S, Gorren AC, Schmidt K, Werner ER, Hansert B, Bohle DS, et al. Metabolic fate of peroxynitrite in aqueous solution. J Biol Chem 1997; 272:3465-3470.
21. Bosse HM, Bachman S. Immunohistochemically detected protein nitration indicates sites of renal nitric oxide release in Goldblatt Hypertension. Hypertension 1997; 30:948-952.
22. Maxwell SR. Prospects for the use of antioxidant therapies. Drugs 1995; 49:345-361.
23. 2 ·), superoxide dismutases, and related matters. J Biol Chem 1997; 272:18515-18517.
24. Tasinato A, Boscoboinik D, Bartoli G-M, Maroni P, Azzi A. D-α-Tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of antioxidant properties. Proc Natl Acad Sci USA 1995; 92:12190-12194.
25. Anderson ME. Glutathione and glutathione delivery compounds. Adv Pharmacol 1997; 38:65-78.
26. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19:227-250.
27. Spapen H, Zhang H, Vincent J-L. Potential therapeutic value of lazaroids in endotoxemia and other forms of sepsis. Shock 1997; 8:321-327.
28. Greenwald RA. Superoxide dismutase and catalase as therapeutic agents for human diseases. A critical review. Free Radic Biol Med 1990; 8:201-209.
29. Schewe T. Molecular actions of ebselen an antiinflammatory antioxidant. Gen Pharmacol 1995; 26:1153-1169.
30. Cash CD. Are the reactive oxygen-derived species (ROS) interactive properties of many therapeutic drugs from various categories pertinent to their beneficial effects? Gen Pharm 1997; 28:169-175.
31. Roffolo RR, Feuerstein GZ, Ohlstein EH. Recent observations with β-adrenoreceptor blockade. Am J Hypertens 1998; 11:9S-14.
32. Grunfeld S, Hamilton CA, Mesaros S, McClain SW, Dominiczak AF, Bohr DF, et al. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertens 1995; 26:854-857.
33. Suzuki H, Swei A, Zweifach BW, Schmid-Schönbein GW. In vivo evidence for microvascular oxidative stress in spontaneously hypertensive rats. Hydroethidine microfluorography. Hypertension 1995; 25:1083-1089.
34. Swei A, Lacy F, DeLano FA, Schmid-Schönbein GW. Oxidative stress in the Dahl hypertensive rat. Hypertension 1997; 30:1628-1633.
35. Vaziri ND, Ding Y, Ni Z, Gonick HC. Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: effect of lazaroid therapy. Kidney Int 1997; 52:1042-1046.
36. Beck Laursen J, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95:588-593. This study shows that hypertension and endothelial dysfunction induced by an infusion of angiotensin II can be partly blocked by SOD.
37. Auch-Schwelk W, Katusic ZS, Vanhoutte PM. Contractions to oxygen-derived free radicals are augmented in aorta of spontaneously hypertensive rat. Hypertension 1989; 13:859-864.
38. Cosentino F, Patton S, d'Uscio LV, Werner ER, Werner-Falmayer G, Moreau P. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998; 101:1530-1537.
39. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97:1916-1923.
40. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991; 88:10045-10048.
41. Schnackenberg CG, Welch WJ, Wicox CS. Normalization of BP and RVR in SHR with a membrane-permeable SOD mimetic: role of NO. Hypertension 1998; 32:59-64. This study shows that the inhibition of NOS abolishes the blood pressure lowering effect of SOD in the SHR.
42. Bouloumié A, Bauersachs J, Linz W, Schälken BA, Wiemer G. Fleming I, Busse R. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension 1997; 30:934-941.
43. Kumar KV, Das UN. Are free radicals involved in the pathobiology of human essential hypertension? Free Radic Res Commun 1993; 19:59-66.
44. Tse WY, Maxwell SR, Thomason H, Blann A, Thorpe GH, Waite M, Holder R. Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J Hum Hypertens 1994; 8:843-849.
45. Lacy F, O'Connor DT, Schmid-Schönbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 1998; 16:291-303. This study found that levels of hydrogen peroxide in plasma are increased in individuals with a family history of essential hypertension, suggesting that increases in ROS may precede the onset of hypertension.
46. Ness AR, Chee D, Elliot P. Vitamin C and blood pressure - an overview. J Hum Hypertens 1997; 11:343-350. This is a review of the literature on epidemiological studies and clinical trials of vitamin C and hypertension.
47. Solzbach U, Hornig B, Jeserich M, Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 1997; 96:1513-1519. This study demonstrates that endothelium-dependent vasodilation in the coronary arteries of hypertensive individuals is improved by vitamin C.
48. Garcia CE, Kilcoyne CM, Cardillo C, Cannon III RO, Quyyumi AA, Panza JA. Effect of copper-zinc superoxide dismutase on endothelium-dependent vasodilation in patients with essential hypertension. Hypertension 1995; 26:863-868.
49. Cardillo C, Kilcoyne CM, Cannon III RO, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasomotor function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997; 30:57-63.
50. Ceriello A, Giugliano D, Quatraro A, Lefebvre PJ. Antioxidants show an antihypertensive effect in diabetic and hypertensive subjects. Clin Sci 1991; 81:739-742.
51. Galley HF, Thornton J, Howdle PD, Walker BE, Webster NR. Combination oral antioxidant supplementation reduces blood pressure. Clin Sci 1997; 92:361-365. This randomized, double-blinded, placebo-controlled trial in patients with essential hypertension demonstrated that treatment with a combination of anti-oxidant vitamins and zinc decreases systolic blood pressure and increases urinary excretion of nitric oxide metabolites.
52. Ghosh SK, Ekpo EB, Shah IU, Girling AJ, Jenkins C, Sinclair AJ. A double-blind, placebo-controlled parallel trial of vitamin C treatment in elderly patients with hypertension. Gerontology 1994; 40:268-272.
53. Hubel CA, Kagen VE, Kisin ER, McLaughlin MK, Roberts JM. Increased ascorbate radical formation and ascorbate depletion in plasma from women with preeclampsia: implications for oxidant stress. Free Radic Biol Med 1997; 23:597-609.
54. Gülmezoglu AM, Hofmeyr GJ, Oosthuisen MM. Antioxidants in the treatment of severe pre-eclampsia:an explanatory randomised controlled trial. Br J Obstet Gynaecol 1997; 104:689-696.
55. Cavanagh EM, Fraga CG, Ferder L, Inserra F. Enalapril and captopril enhance antioxidant defenses in mouse tissues. Am J Physiol 1997; 272:R514-518.
56. Djordjevic VB, Pavlovic D, Pejovic M, Cvetkovic T, Lecic N, Deihanin-Ilic M. Changes of lipid peroxides and antioxidative factors in blood of patients treated with ACE inhibitors. Clin Nephrol 1997; 47:243-247.
57. Maggi E, Marchesi E, Covini D, Negro C, Perani G, Bellomo G. Protective effects of carvedilol, a vasodilating β-adrenergic blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996; 27:532-538.
58. Moser M, Frishman W. Results of therapy with carvedilol, a β-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens 1998; 11:15S-22S.
59. Price JF, Fowkes FG. Antioxidant vitamins in the prevention of cardiovascular disease. Eur Heart J 1997; 18:719-727.
60. Tardif J-C, Côté G, Lespérance J, Bourassa M, Lambert J, Doucet S et al. Probucol and multivitamins in the prevention of the restenosis after coronary angioplasty. N Engl J Med 1997; 337:365-372.
61. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH and the US Carvedilol Heart Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1355.